Novo Nordisk A/S News - October 2026
Novo Nordisk Prepares to Announce Next-Generation Weight-Loss Drug Trial Results
Novo Nordisk is reportedly preparing to announce clinical trial results for a next-generation weight-loss drug. The company has not disclosed details about the...
Novo Nordisk's Patent Wall Is Crumbling — Can Its Pipeline Outrun the Generic Tide?
Shares of Novo Nordisk edged up 0.2% to $254.30 on Oct. 10, a muted reaction to a potentially seismic development: the European Patent Office's Board of...
Novo Nordisk Loses Patent, Threatening Ozempic and Wegovy Exclusivity From 2031
The European Patent Office’s (EPO) Board of Appeal revoked Novo Nordisk’s patent EP 3 448 416, which covered its semaglutide products Wegovy and Ozempic. The...
Novo Nordisk Presents Early Data Linking Semaglutide to Longer Life
At the ARDD conference, Novo Nordisk presented early data suggesting its GLP-1 receptor agonists, including semaglutide, may support healthier aging and longer...